InsiderClue
← All stocks

Monte Rosa Therapeutics, Inc.

GLUE Net selling
CIK 0001826457 #2381 in the set updated 19 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$4.11M
$436.05K on a plan · $2.68M straight out of an exercise
Sold at will
$999.39K
11 of 36 sales
Net
−$4.11M
−$999.39K against sales at will

By person

11 insiders · 36 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Janku Filip
Chief Medical Officer
—
$1.38M (6) scheduled
−$1.38M
60,612
0.0710%
$1.41M
+413.6%
Warmuth Markus
President & CEO
—
$951.14K (10)
−$951.14K
585,038
0.6858%
$13.56M
+40.5%
Dunn Edmund
Principal Accounting Officer
—
$483.14K (4) scheduled
−$483.14K
22,554
0.0264%
$522.82K
+61.7%
Townson Sharon
Chief Scientific Officer
—
$423.93K (6) scheduled
−$423.93K
67,845
0.0795%
$1.57M
—
Manning Anthony M.
Director
—
$411.20K (2) scheduled
−$411.20K
0
0.0000%
$0.00
—
Champoux Jennifer
Chief Operating Officer
—
$311.30K (6) scheduled
−$311.30K
62,371
0.0731%
$1.45M
—
Nickson Philip
Chief Business & Legal Officer
—
$151.27K (2)
−$151.27K
55,000
0.0645%
$1.27M
—
Versant Venture Capital VI, L.P. entity
10% owner
—
—
—
5,652,922
6.63%
$131.04M
−32.1%
Bowen Matthew
Principal Accounting Officer
—
—
—
25,904
0.0304%
$600.48K
+19.9%
Leo Chandra P.
Director
—
—
—
10,000
0.0117%
$231.81K
—
Behbahani Ali
Director
—
—
—
0
0.0000%
$0.00
−100.0%

Individual transactions

7
Insider
Date
Role
Action
Shares
Price
Amount
Warmuth Markus
1 Jun 2026
President & CEO
Sold on a plan
468
$19.73
$9.23K
Warmuth Markus
1 Jun 2026
President & CEO
Sold on a plan
4,998
$19.41
$97.02K
Warmuth Markus
1 May 2026
President & CEO
Sold on a plan
5,467
$18.92
$103.45K
Warmuth Markus
2 Mar 2026
President & CEO
Sold on a plan
5,466
$17.92
$97.97K
Warmuth Markus
7 Jan 2026
President & CEO
Sold on a plan
309
$24.57
$7.59K
Warmuth Markus
7 Jan 2026
President & CEO
Sold on a plan
1,450
$23.88
$34.62K
Warmuth Markus
7 Jan 2026
President & CEO
Sold on a plan
3,707
$23.24
$86.16K
Show all 36 transactions →

What was left out

Form 4 filings counted 39
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 18
Sales at will 11
Transactions with no price 0
Shares from compensation/vesting 1,377,460
History held since 25 Jun 2021